37results about How to "Useful to treat and prevent" patented technology

Provided are bis-quaternary ammonium compounds which are modulators of nicotinic acetylcholine receptors. Also provided are methods of using the compounds for modulating the function of a nicotinic acetylcholine receptor, and for the prevention and / or treatment of central nervous system disorders, substance use and / or abuse, and or gastrointestinal tract disorders.

The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.

The present invention relates to novel tricyclic derivative compounds, and more specifically to tricyclic derivative compounds, optical isomers thereof, racemates thereof, or pharmaceutically acceptable salts thereof, which have excellent activity against PARP-1, tankyrase-1 or tankyrase-2. The tricyclic derivative compounds, optical isomers thereof, racemates thereof or pharmaceutically acceptable salts thereof according to the present invention have inhibitory activity against PARP-1, tankyrase-1, or tankyrase-2, and thus can be effectively used for the prevention or treatment of neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic neuropathy, inflammatory diseases, osteoporosis, or cancer.

The present invention relates to a heteroaryl derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition for preventing or treating diseases associated with PI3 kinases, containing the same as an active ingredient. The heteroaryl derivative according to the present invention has an excellent effect of selectively inhibiting PI3 kinases, thereby being useful in preventing or treating PI3 kinase diseases such as: cancers, autoimmune diseases, and respiratory diseases.

The present invention relates to a solid composition comprising an iodine agent and sodium chloride having improved water solubility and to an antiviral and antimicrobial composition for an eye, oral cavity, nasal cavity or inhalation containing an aqueous solution thereof, wherein the solid composition comprises an iodine agent and sodium chloride or a mixture of an iodine agent, sodium chloride and a flavoring agent and is excellent in not only storage stability but also water solubility as a dissolution rate thereof for water is 30 seconds or less. In addition, the aqueous solution in which the solid composition is dissolved in water has an excellent effect of shielding from the unpleasant or irritating odor and taste of an iodine agent while also not causing pain or irritation, has an outstanding effect of preventing or treating infectious respiratory diseases such as a cold or influenza, and is applicable to all parts of a respiratory organ, such that the solution can be usefully used for the prevention or treatment of respiratory infectious diseases.

The present invention refers to a pharmaceutical preparation for treating inflammatory diseases and microbial infections comprising a pharmaceutically effective amount of ozone and at least one monomeric amino acid having an oxidation-sensitive side chain, or at least one ozonized monomeric amino acid having an oxidation-sensitive side chain.Also described is the use of a preparation as described before for providing a medicament for treating inflammatory diseases, microbial infections and for immune modulation. The pharmaceutical preparation according to the invention is particularly useful in the treatment of oral inflammations.

The invention is in the field of prevention and medical treatment of liver diseases, in particular non-alcoholic steatohepatitis (NASH). The invention provides means and methods for the treatment of hepatic inflammation, fibrosis and more in particular NASH. More in particular, the invention provides a composition capable of raising anti-oxLDL antibodies in vivo for use in the treatment of liver inflammation or fibrosis.

The present invention refers to a pharmaceutical preparation for treating inflammatory diseases and microbial infections comprising a pharmaceutically effective amount of ozone and at least one monomeric amino acid having an oxidation-sensitive side chain, or at least one ozonized monomeric amino acid having an oxidation-sensitive side chain.Also described is the use of a preparation as described before for providing a medicament for treating inflammatory diseases, microbial infections and for immune modulation. The pharmaceutical preparation according to the invention is particularly useful in the treatment of oral inflammations.

The present invention relates to a compound represented by chemical formula 1, which can be used for the prevention and treatment of diseases caused by abnormality in a prolyl-tRNA synthetase (PRS) activity, or a pharmaceutically acceptable salt thereof, a method for preparing the same, and a pharmaceutical composition comprising the same.

An antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof, and use thereof, are provided. The antibody that specifically binds to ErbB3 or an antigen-binding fragment thereof may be effectively used to prevent or treat a disease related to activation or overexpression of ErbB3 protein.

The present invention provides: a peptide having antibacterial activity; a composition for preventing or treating sepsis comprising same; and an antibacterial composition. More specifically, the peptide according to the present invention has the excellent effects of not only suppressing the growth of bacteria but removing endotoxins derived from bacteria, thus exhibiting an excellent therapeutic effect on sepsis, and thus can be usefully used to prevent or treat sepsis. In addition, the peptide according to the present invention has selectively excellent antibacterial activity against Gram positive / negative bacteria, and thus can be usefully used in an antibacterial composition for Gram-positive / negative bacteria, or to prevent or treat various infectious diseases caused by Gram-positive / negative bacteria. Furthermore, the peptide according to the present invention exhibits excellent resistance against proteolytic enzymes, and is highly stable, and thus is expected to be utilized in various forms, such as a pharmaceutical composition, a cosmetic composition, a food composition, a health food composition, a feed composition, and a quasi-drug composition.

The present invention relates to a pharmaceutical composition for preventing or treating neurodegenerative diseases comprising a diterpene, or a pharmaceutically acceptable salt thereof.Specifically, the diterpene of the present invention can prevent or treat neurodegenerative diseases caused by inhibition of Nurr1 activity by activating Nurr1 and inhibiting the inflammatory response.

The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.

The present invention relates to a compound exhibiting excellent agonist activity against melanocortin receptors. More specifically, the present invention relates to a compound of Formula 1, a pharmaceutical composition comprising the compound as an active ingredient, and a use thereof, and the compound of the present invention exhibits excellent agonist activity against melacortin-4 receptors and can be particularly useful in preventing or treating obesity, diabetes, inflammation and erectile dysfunction.

The present invention provides a compound represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof which can be effectively used for preventing or treating obesity or metabolic syndrome, and a pharmaceutical composition comprising the same.in Chemical Formula 1,R1 and R2 are the same as defined in the specification.

The present invention relates to a pharmaceutical composition containing a G protein coupled receptor 119 (GPR119) ligand as an effective ingredient for preventing or treating non-alcoholic steatohepatitis. More particularly, it was confirmed that the GPR119 ligand, which has been developed as only an anti-diabetic drug, exhibits superior effects on the treatment of non-alcoholic fatty liver and the signal pathways in hepatocytes therefor differ from the signal pathways in the small intestine and the pancreas exhibiting anti-diabetic effects, whereby the GPR119 ligand can be useful to treat non-alcoholic steatohepatitis.

An Nkx3.2 fragment with improved stability under a histopathological environment of arthritis and a pharmaceutical composition containing the Nkx3.2 as an active ingredient are disclosed. The Nkx3.2 fragment has a function to activate NF-κB at the similar level to full-length Nkx3.2 and resistance to proteolysis by Siah1. In addition, the Nkx3.2 fragment exhibited at least a 10-fold improvement in degenerative arthritis treatment effect compared with Nkx3.2 in an animal model-based in vivo efficacy evaluation. Therefore, the Nkx3.2 fragment can be favorably used in the prevention or treatment of arthritis.

An anti-tau antibody according to the present invention specifically binds to a tau protein, in which the 280th lysine is acetylated. The antibody can inhibit aggregation of abnormal tau proteins. The antibody can improve the motor function and cognitive function of animal models. It can be effectively used for preventing or treating a degenerative neurological disease.

The present invention relates to a novel compound as an mTOR inhibitor and a use thereof and, more specifically, to a novel compound represented by formula 1 that exhibits mTOR inhibitory activity and a pharmaceutical composition comprising same as an active ingredient for preventing or treating brain diseases associated with an mTOR pathway.

The present invention relates to a method by use of a pharmaceutical composition for preventing or treating inflammatory disease, colorectal cancer and prostate cancer, which contains an A3 adenosine receptor agonist, 2-chloro-N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-Cl-IB-MECA), N6-(3-iodobenzyl)-4′-thioadenosine-5′-N-methyluronamide (thio-IB-MECA), or a pharmaceutically acceptable salt thereof. The pharmaceutical composition of the invention is significantly less toxic than conventional A3 adenosine agonists, and thus is useful for prevention or treatment of inflammatory disease. In addition, it more selectively inhibits the growth of androgen receptor-dependent or independent prostate cancer cells than other A3 adenosine receptor agonists and thus is useful for prevention or treatment of colorectal cancer or prostate cancer.

Provided is a pharmaceutical composition for inhibiting angiogenesis, comprising a therapeutically effective amount of a compound represented by Formula 1: (I) wherein R1 through R13 and X are as defined in the specification. Compounds used as an active ingredient in the pharmaceutical composition of the present invention bind to QP-C to provide effective prevention of angiogenesis and can be effectively used for prevention and / or treatment of angiogenesis-related diseases or disorders. Further, the active compounds of the present invention inhibit biological functions of QP-C, which consequently leads to inhibition of angiogenic responses without the risk of cellular apoptosis, thus significantly improving safety of the drug.

Provided is a novel oral mucosa application material that has good handling properties, has excellent application properties for being applied to the oral mucosa even if moisture or saliva on the surface of the oral mucosa is heavy, and is provided with a property for improving the effect of physically protecting an application site by containing the moisture or saliva after application and showing elasticity, and further, a property for remaining at the application site for a long time. This oral mucosa application material is provided with a freeze-dried body containing a polymer on an adhesion surface to the oral mucosa. The content of the polymer in the freeze-dried body is 20 mass % or more, and the content of hyaluronic acid in the polymer is 50 mass % or more.

The present invention relates to a pharmaceutical composition comprising a thiourea derivative or its pharmaceutically acceptable salt, a cyclodextrin or its derivative; and a pharmaceutical formulation comprising same.